title: [A case of advanced gastric cancer resistant to S-1 successfully treated with weekly administration of paclitaxel].
abstract: A 62-year-old female was diagnosed with type 2 advanced gastric cancer in May 2003. Pathological examination showed a poorly differentiated carcinoma. Computed tomography (CT) revealed paraaortic lymph node metastasis, duodenal metastasis and ascites due to peritoneal dissemination. Chemotherapy with CDDP+S-1 was started and continued. After the chemotherapy, there were progressive diseases. Therefore, paclitaxel (PTX) was administered at a dose of 80 mg/m2/day for 3 weeks followed by a week rest. Clinical symptoms were relieved, and CT scan revealed metastatic lymph nodes were reduced after 4 cycles. After 13 cycles, MRI revealed a solitary brain mass was detected. She was resected for a right temporal-occipital brain metastatic tumor, and local cerebral irradiation was performed. After this operation, she was diagnosed with brain metastasis from advanced gastric cancer. The procedure was interrupted for about 6 months. After rehabilitation, PTX treatment was restarted as 14th cycle. She has survived without recurrence more than 30 cycles after the resection. A weekly administration of PTX may be a promising regimen as second-line chemotherapy for S-1 resistant recurrent gastric cancer.
authors.affiliation: Dept. of Surgery, Ogikubo Hospital.
authors.forename: Nobushige
authors.initials: N
authors.lastname: Yabe
authors.forename: Shinji
authors.initials: S
authors.lastname: Murai
authors.forename: Tomotaka
authors.initials: T
authors.lastname: Akatsu
authors.forename: Takahiro
authors.initials: T
authors.lastname: Shoji
authors.forename: Hirotomo
authors.initials: H
authors.lastname: Shimizu
authors.forename: Hideki
authors.initials: H
authors.lastname: Fukushima
authors.forename: Yosuke
authors.initials: Y
authors.lastname: Mitsugi
authors.forename: Takashi
authors.initials: T
authors.lastname: Ishida
authors.forename: Tetsu
authors.initials: T
authors.lastname: Amemiya
authors.forename: Hirotoshi
authors.initials: H
authors.lastname: Hasegawa
authors.forename: Yuko
authors.initials: Y
authors.lastname: Kitagawa
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D001932:Brain Neoplasms / Q000556:secondary; D002277:Carcinoma / Q000188:drug therapy* / Q000473:pathology; D004334:Drug Administration Schedule; D004338:Drug Combinations; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D008875:Middle Aged; D010094:Oxonic Acid / Q000627:therapeutic use*; D017239:Paclitaxel / Q000008:administration & dosage*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005641:Tegafur / Q000627:therapeutic use*
chemical_list: D000964:Antimetabolites, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D017239:Paclitaxel